Our leadership

Fidia is one of the very few companies worldwide that produces Hyaluronic Acid-based products which are commercialized in the US, thus confirming the high quality standards of Fidia's production process, i.e. maximum purity of raw material and safety of the finished products.

Being a natural component of the human body, Hyaluronic Acid (HA) is totally biocompatible, non-immunogenic and non-toxic. Thanks to these unique characteristics, Hyaluronic Acid and its derivatives can be used in many areas of medicine, such as rheumatology, orthopedics, tissue repair, aesthetics, dermatology, and ophthalmology.

More than 55 years of researching this molecule have made Fidia at the forefront of the production of both natural and functionalized Hyaluronic Acid using proprietary and certified manufacturing processes, with different ranges of molecular weight, according to the desired characteristics of the finished products.

In addition, Fidia's breakthrough patented technology process allows to chemically modify the molecule in order to obtain suitable derivatives, with different physical and biological properties, to improve the quality of care and best meet an individual patient's needs.

- 1963: first HA-based product ever (topical application)

- 1987: first HA-based products for intra-articular administration

Farmaceutici S.p.A.

Find out our Corporate Website:

Go to the website

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.